Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling